DRI vs RPRX: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
RPRX is the larger of the two ($39.40B market cap): the incumbent the market prices for continued execution (11.63x forward earnings, beta 0.36). DRI is the smaller challenger ($26.00B), actually pricier on forward earnings (18.54x): more room to run, but more to prove. If you believe DRI earns its premium (18.54x forward earnings, so the market expects more from it), DRI fits. If you believe in paying less for profit, RPRX fits at 11.63x.
DRI vs RPRX: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | DRI | RPRX | What it tells you |
|---|---|---|---|
| Market cap | $26.00B | $39.40B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 18.54 | 11.63 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 22.31 | 44.79 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.63 | 0.36 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 85% of range | 94% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 12.59 | 4.47 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: RPRX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how DRI and RPRX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DRI and RPRX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DRI and RPRX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Darden Restaurants (DRI) do?
Darden Restaurants is the largest full-service restaurant company in the United States by revenue, operating more than 2,000 locations across a portfolio of brands and employing about 210,000 people. Its two volume engines are Olive Garden, the casual Italian chain that is its flagship, and LongHorn Steakhouse. Beyond those, Darden owns a cluster of fine-dining and specialty concepts including The Capital Grille, Eddie V's, Ruth's Chris Steak House (acquired in 2023), Yard House, Cheddar's Scratch Kitchen, Seasons 52, Bahama Breeze, and Chuy's, a Tex-Mex chain it acquired in late 2024 in a roughly ~$605 million all-cash deal.
What does Royalty Pharma (RPRX) do?
Royalty Pharma plc buys the right to receive royalties on approved and development-stage biopharmaceutical products. A university, a research hospital, a small-cap biotech or a large pharmaceutical company owns a royalty on a drug; Royalty Pharma pays a lump sum, sometimes staged across milestones, and thereafter receives a percentage of that drug's top-line sales. The portfolio spans more than 35 marketed therapies and 19 development-stage candidates. In the second quarter of 2026 the largest contributors were Vertex's cystic fibrosis franchise at $194 million of Royalty Receipts, Biogen's Tysabri at $67 million, GSK's Trelegy at $58 million, Johnson & Johnson's Tremfya at $57 million, Roche's Evrysdi at $47 million and Servier's Voranigo at $46 million. Founded in 1996 and public since 2020, the company is incorporated in England and Wales, headquartered in New York, and lists only its Class A ordinary shares on Nasdaq. Until May 16, 2025 it was externally managed and paid a quarterly fee of 6.5% of royalty cash receipts plus 0.25% of security investments; that manager was bought in, and the staff now sit inside the company.
DRI vs RPRX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- DRI drivers: Olive Garden and LongHorn carry the volume; Growth through acquisitions and new units.
- RPRX drivers: Royalty Receipts are outrunning the headline receipts number; The internalisation permanently changed the cost line.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Darden's results hinge on discretionary consumer spending, so a weaker economy or pressured household budgets can slow restaurant traffic and shrink average checks. For RPRX, concentration is the first thing to size.
DRI or RPRX: which should you pick?
If the story you believe is DRI's (Olive Garden and LongHorn carry the volume), DRI is the more direct way to own it; if it is RPRX's (Royalty Receipts are outrunning the headline receipts number), RPRX is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DRI and RPRX guides.
DRI vs RPRX: the full fundamentals
DRI. At about $230 Darden trades near 22 times trailing and 18.5 times forward earnings, near the top of its 52-week range of about $170 to $240 and just below the roughly $233 average analyst target, so the 23% gain this year has used up most of the gap to that target. The valuation leans on steady mid-single-digit sales growth, scale advantages and a dividend yielding about 2.8%. The December 18, 2026 report, with consensus EPS of about $2.25, is the next test.
RPRX. The ~15 times sales a screener prints comes from dividing a ~$39 billion market cap by ~$2.6 billion of GAAP revenue, which is the wrong denominator for this structure. Measured against the $3.5 billion to $3.55 billion of Portfolio Receipts guided for 2026, the same market cap is about 11 times. The gap between the trailing P/E near 45 and a forward P/E near 11.6 is the same effect seen from the earnings side, with non-cash provisions and impairments compressing reported profit while cash collections keep rising; eight analysts carry a mean target near $73.50, about 7% above the November 20 close.
Headline figures (approximate, November 2026): DRI shows revenue (ttm) ~$13.37 billion, q1 fy2027 revenue ~$3.2 billion, up ~5%; EPS $2.05, in line, margins (ttm) ~22% gross, ~12% operating, ~9% net, net income (ttm) ~$1.19 billion; RPRX shows revenue (ttm, gaap) ~$2.62 billion on a trailing basis as of the third quarter of 2026 (Yahoo Finance), against $2,378 million of total income and other revenues in fiscal 2025, $2,264 million in 2024 and $2,355 million in 2023. GAAP quarterly income was ~$690 million in the third quarter of 2026 and $674 million in the second, of which $638 million was income from financial royalty assets and $36 million other royalty income. The line is not a sales figure in the ordinary sense: it is the interest component of royalty collections, accreted under the effective interest method off sell-side consensus sales forecasts, so it moves when analysts revise the drugs Royalty Pharma has bought into., portfolio receipts (the operating measure) $3,254 million in 2025, up 16% from $2,801 million in 2024, $1,698 million in the first half of 2026, up 8.4% from $1,566.8 million, and ~$890 million in the third quarter. Royalty Receipts, the sales-linked core, were $3,127 million in 2025 and $1,655 million in the first half of 2026 (up 13.4%). Guidance raised for the third time on November 4, 2026 puts full-year Portfolio Receipts at $3,500 million to $3,550 million, up from $3,400 million to $3,500 million in August., earnings and eps Diluted EPS of ~$1.53 on a trailing twelve-month basis, on ~$672 million of net income attributable to Royalty Pharma plc; GAAP net income was $770.95 million in fiscal 2025 and $858.98 million in 2024. The quarterly path is erratic by design: first-half 2026 diluted EPS was $0.71 on $312.6 million attributable to the plc, the second quarter alone was $0.04 after a $268 million provision for changes in expected cash flows, and the third quarter brought ~$145 million attributable to the plc. Consolidated net income of $549.7 million in the first half was reduced by $237.2 million attributable to non-controlling interests before reaching Class A holders., cash flow and adjusted ebitda Net cash provided by operating activities was $1,447 million in the first half of 2026 against $960 million a year earlier, and $2,490 million for full-year 2025. Adjusted EBITDA, defined in the credit agreement as Portfolio Receipts less payments for operating and professional costs, was $736 million in the second quarter and roughly $3.2 billion trailing; Portfolio Cash Flow, after net interest, was $736 million in the quarter and $2,724 million in 2025. Payments for operating and professional costs ran at 4.8% of Portfolio Receipts in the quarter versus 8.9% for all of 2025..
The bottom line: DRI vs RPRX
DRI and RPRX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined DRI and RPRX exposure against your real portfolio. It is not an investment adviser.
Wondering how DRI or RPRX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Darden Restaurants
Ask Walnut's AI anything about DRI and see how it fits what you own.
FAQ
What is the difference between DRI and RPRX?
+
Darden Restaurants is the largest full-service restaurant company in the United States by revenue, operating more than 2,000 locations across a portfolio of brands and employing about 210,000 people. Royalty Pharma plc buys the right to receive royalties on approved and development-stage biopharmaceutical products. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is DRI or RPRX the better stock?
+
Neither is universally better. RPRX is the larger incumbent; DRI is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, DRI or RPRX?
+
On forward P/E (as of November 2026), DRI trades at 18.54x and RPRX at 11.63x, so RPRX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both DRI and RPRX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of DRI vs RPRX?
+
DRI: Darden's results hinge on discretionary consumer spending, so a weaker economy or pressured household budgets can slow restaurant traffic and shrink average checks. Food and labor inflation are persistent headwinds that can compress margins faster than menu prices can offset, and raising prices too much risks losing value-seeking diners; earnings in the latest quarter were down about 7% year over year even as revenue grew about 5%. The casual and fine-dining categories are crowded and competitive, with rivals such as Texas Roadhouse, Chili's, and fast-casual chains fighting for the same guests. Integrating acquisitions like Chuy's also carries execution risk. The balance sheet is more leveraged than the brand image suggests, with about $8.6 billion of debt (including lease obligations) against about $0.2 billion of cash. RPRX: Concentration is the first thing to size. Vertex's cystic fibrosis franchise supplied 32% of total income and other revenues in the second quarter of 2026 and 33% across the half, and its $194 million of quarterly Royalty Receipts were flat year on year. That royalty is perpetual in contract but the company models a 2039 to 2041 duration on expected Alyftrek patent expiry. There is also an unresolved dispute with the payor: beginning in the second quarter of 2025 Royalty Pharma did not receive what it believes it is contractually owed on Alyftrek net sales and has commenced the contractual dispute resolution procedures, with any recovery recognised only if the matter resolves in its favour. Individual royalties can also go to zero, and development-stage ones can fail outright: pelacarsen's Phase 3 outcomes trial missed its primary endpoint in September 2026. Ipsen and Eisai withdrew Tazverik across all indications in March 2026, producing a $69.4 million non-cash impairment and the gross write-off of a $548.3 million financial royalty asset. Promacta receipts fell 75% in the quarter on US generic entry and Imbruvica fell 17%, both real cash declines that the growers merely offset. Reported earnings swing on estimates rather than operations: the provision for changes in expected cash flows was a $268 million charge in the second quarter of 2026 against a $204 million benefit a year earlier, which is why net income attributable to the plc fell to $17.9 million and diluted EPS to $0.04. Leverage of $9.2 billion at June 30 (about $8.6 billion at September 30) sits ahead of shareholders and drove $187.3 million of interest expense in the half. Tax is a live question too: the company records no income tax expense today, and it flags the UK's adoption of the Pillar Two 15% global minimum tax rules alongside its own statement that its tax position is not free from doubt. Finally, the share price now carries more expectation than it did a year ago: up about 78% over twelve months, near its 52-week high of $70.37 and slightly below the ~$73.50 mean analyst target, it trades on the assumption that receipts growth keeps compounding, and the Alyftrek dispute with Vertex remains unresolved.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell DRI or RPRX; figures are approximate and dated (as of November 2026). Verify current data before investing.